The aesthetics business is booming, and the numbers show it. On March 3, Evolus reported nearly 300 million dollars in 2025 revenue, a sixth straight year of double-digit growth for the maker of Jeuveau.
On March 3, 2026, Evolus reported full-year 2025 results, with the company stating it generated nearly 300 million dollars in total net revenue, its sixth consecutive year of double-digit growth, led by the neurotoxin Jeuveau and its expanding Evolysse hyaluronic acid filler line. The results illustrate continued strong consumer demand in aesthetics.
Earnings season is an unglamorous but revealing window into aesthetics, and Evolus report in early March was a notable data point.
The numbers reflect a category still growing briskly despite a crowded field.
Evolus, maker of the aesthetics-only neurotoxin Jeuveau (prabotulinumtoxinA) and the Evolysse line of hyaluronic acid fillers, announced 2025 financial results on March 3, 2026, reporting nearly 300 million dollars in total net revenue and characterizing it as a sixth straight year of double-digit growth. The company also pointed to expanding share for Jeuveau in the U.S. and internationally and to the contribution of its newer filler portfolio, while issuing 2026 guidance emphasizing operating leverage and improving profitability.
For context, Jeuveau competes with toxins including Botox, Dysport, Xeomin, and Daxxify, and the filler market is similarly competitive. Strong results from a mid-sized, aesthetics-focused company underscore that consumer demand for injectables remained robust heading deeper into 2026, even as new products and price competition reshape the landscape.
For consumers, company results are an indirect but useful signal: sustained growth means continued investment, marketing, and competition, which can expand access and options but also intensify promotional noise. Market success is not a measure of whether a given product is right for an individual. The constant remains a qualified provider, an authentic product, and a plan matched to personal goals rather than to whichever brand is advertising hardest.
Watch how competition among toxin and filler makers affects pricing, loyalty programs, and product availability through 2026, and whether newer entrants and formulations shift market share. For patients, the practical lens is to treat brand marketing as marketing: ask about the specific product, its FDA-approved uses, and your provider experience with it, rather than choosing based on whichever company is growing fastest.